Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences

OGA inhibitors offer multimodal mechanism of action with potential for multiple approaches to clinical development in Alzheimer’s and Parkinson’s disease

Lausanne, SWITZERLAND and San Francisco, CA, USA, 30 September 2021 – Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases such as the intracellular aggregation of the microtubule-associated protein tau, is pleased to announce that the Company will be presenting novel data on its O-GlcNAcase (OGA) inhibitor pipeline at the following upcoming conferences.

Read more…


By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...